Conditions: Multiple Myeloma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 222
Healthy volunteers: no

Brief summary:
Randomized, open-label, international, multi-center, Phase 3 study in which patients are randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.

Detailed description:

Arms:
arm 1: VELCADE administered by subcutaneous injection arm 2: VELCADE administered by intravenous infusion

Interventions: intervention 1: VELCADE Administered by subcutaneous injection intervention 2: VELCADE Administered by intravenous infusion
Intervention descriptions: intervention 1: Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle intervention 2: Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.

Protocol document: